Luxury sector faces more gloom as Bain cuts sales forecast
MILAN/PARIS, May 14 (Reuters) - Sales of luxury goods worldwide are likely to fall between 2% and 5% this year, consultancy Bain & Co forecast on Wednesday, sharply downgrading its previous estimate for 0-4% growth and signalling further gloom for the sector after 2024's 1% drop.
Ahead of its closely-watched spring report, Bain said the luxury market was experiencing "more complex turbulence across multiple axes".
It cited economic pressures and price fatigue over the first three months of the year, and noted shoppers were waiting for new, more creative products from brands.
Bain's previous forecast for flat sales to 4% growth was issued in November.
Top labels including Gucci, Chanel and Dior have appointed new designers as the sector faces its worst downturn in years, with a property crisis weighing on the Chinese market and U.S. shoppers pulling back amid economic uncertainty.
The new forecast comes as the industry braces for further economic turbulence following a global flare-up in trade tensions.
While the large majority of luxury shoppers polled by the consultancy, 75%, said tariffs would not likely cause them to make fewer luxury purchases in the future, around half of those who had already pulled back over the past year said it was due to price increases in the sector.
Many luxury brands capitalised on the post-pandemic surge in sales to make their biggest ever price increases in recent years, analysts say.
Executives of designer fashion brands had hoped at the start of the year for a U.S.-led turnaround, after improvements over the end-of-year holiday season, but by mid-February signs of weakening demand in the U.S. began to emerge.
(This story has been refiled to correct the day of the week to Wednesday, not Tuesday, in paragraph 1)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
an hour ago
- NBC News
In China, ‘The Great American' burger is now made with Australian beef
At his restaurant in Beijing, Geng Xiaoyun used to offer a special dish of salt-baked chicken feet — or 'phoenix talons' as they are called in China — imported from America. With prices climbing 30% from March due to tariffs, the owner of Kunyuan restaurant had to pull the Chinese delicacy from the menu. 'American chicken feet are so beautiful,' Geng said. 'They're spongy so they taste great. Chinese [chicken] feet just aren't as good.' Geng can now source chicken feet from Brazil or Russia but said they just don't stand up to the American ones. He keeps a small stash for himself but hopes to serve his American phoenix talons once again. 'The price of American chicken feet will come back down,' he said, 'as long as there are no big changes in the world's political situation.' But the 90-day tariff pause agreed by China and the U.S. in Geneva in May is now under threat as both sides have accused each other of breaching the terms. On Monday, the Chinese Commerce Ministry responded to President Donald Trump 's claim that the country 'totally violated its agreement.' The ministry pointed at recent U.S. artificial intelligence chip export controls as actions that 'severely undermine' the Geneva pact. As the world waits and watches, American agricultural products have been vanishing from Chinese stores and restaurants and losing ground to other imports. U.S. Department of Agriculture grade beef has been a draw for years at Home Plate, a Beijing restaurant known locally for its American-style barbecue. However, staff said the restaurant stopped serving American beef last month. Dishes like 'The Great American' burger are made with beef imported from Australia. Australian beef has zero duty under the terms of the China-Australia Free Trade Agreement, though China does maintain the right to a safeguard limit on those imports. Liu Li, a beef supplier at the Sanyuanli market for three decades, said the tariffs have disrupted supply, hiking the price of U.S. beef by 50% compared to before the tariff fight. 'U.S. beef is fattier and tastier,' Li said. 'It's a shame we're in a trade war. The high price is just too much to bear.'
Reuters
15 hours ago
- Reuters
Britain facing race to avoid $1 billion in EU carbon tax costs
LONDON/BRUSSELS, June 2 (Reuters) - Britain will struggle to link its carbon market to the EU's in just seven months, to avoid UK companies facing the bloc's carbon border tariff and annual bills around 800 million pounds ($1.08 billion) from next year, market experts have said. Billed as part of a "reset" in relations after Britain's 2016 exit from the European Union, the two sides announced last month they will link their carbon emissions trading systems by the end of the year. But neither side has set a timeframe or detailed the work that must be done to make this happen before January, when Europe's carbon border tax kicks in. "It's probably still likely to take many years before linkage takes effect. The earliest is 2028, but it's more likely to be 2029 or even 2030," said Ben Lee, senior emissions analyst at Energy Aspects. The UK government said a key upside of linking to the EU's carbon market, or emissions trading system (ETS), is to avoid businesses being hit by the EU's carbon border tariff - which, starting next year, will impose fees on the CO2 emissions associated with imports of steel, cement and other goods. The UK government said avoiding these costs would save 800 million pound a year. But EU officials say to get exempted from the carbon border levy, Britain would need to have linked its carbon market to the EU's. "Full linkage will take several years given the complexity of the process, purely from a technical perspective," ClearBlue carbon market analyst Yan Qin said, adding that an "optimistic" scenario could see the link forged in 2027. A spokesperson for the British government said it will seek to agree a carbon market link as soon as is feasible. "We will not provide a running commentary on the progress of negotiations," they said. To make a link happen, the UK needs to adjust its national rules for issuing carbon trading permits, bring its emissions permit auctions in line with EU rules, and change its national cap on how much companies covered by the carbon market can emit. That's not all. The EU and UK schemes are also not yet aligned on how many free CO2 permits they give industries. And the EU carbon market has a special "reserve" which adds or removes permits from the market to help stabilise prices. Britain's scheme currently lacks a "reserve", though it has a cost containment mechanism that can act as a ceiling on prices, something the EU scheme does not have. "Resolving the question of a supply adjustment mechanism will likely be one of the technical calibrations that will need to be in place before the two systems can link," said Veyt senior analyst Ingvild Sorhus. Some businesses argue these issues are technically straightforward to resolve. "With the right political will, an ETS linking agreement between the EU and UK could be signed within 6 months, and operational by 2028," said Alistair McGirr, Head of Policy and Advocacy at British energy firm SSE. Industry group Energy UK said linkage negotiations could conclude within a year - but that Britain should seek an exemption from the EU carbon border levy until the link is sealed, in case talks drag into 2026. "It is a question not of major political roadblocks, but primarily of technical processes ... I'm not saying these are small problems, but they are simply not intractable problems," Energy UK Policy Director Adam Berman said, of the changes needed to allow the link. The UK plans to launch its own carbon border tariff a year later, in 2027. Brussels may be in less of a hurry. Britain's carbon market is less than a tenth of the size of the EU's, so a link would see British businesses gain access to a much more liquid market. The upside for the EU is less clear - although EU officials cite the bloc's aim to expand carbon pricing internationally, to ensure as many countries as possible put a price on greenhouse gas emissions. Companies also say the move would avoiding competitive distortions and reduce costs for both EU and UK consumers. Pascal Canfin, a French lawmaker in the European Parliament, said the upsides for Britain were more obvious than for the EU. "It's a political move," said Canfin, of the EU's motivation. "The UK was within [the EU] ETS before. I mean, it's not such a big deal to have it again." ($1 = 0.7387 pounds)
Reuters
17 hours ago
- Reuters
Amgen drug cuts small cell lung cancer death risk by 40%
June 2 (Reuters) - Amgen's (AMGN.O), opens new tab Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday. The Phase 3 trial of 509 patients showed that Imdelltra extended median overall survival by more than five months to 13.6 months, compared with 8.3 months for standard-of-care chemotherapy, the company said. The median length of time patients lived without their disease worsening, a measure known as progression-free survival, was 4.2 months for the Imdelltra group and 3.7 months for patients who received chemotherapy. Amgen said the trial results are intended to serve as confirmatory evidence to support last year's accelerated approval by the U.S. Food and Drug Administration of Imdelltra for patients with extensive stage small cell lung cancer whose disease worsened on or after platinum-based chemotherapy. The findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago and published in The New England Journal of Medicine. Most lung cancer cases are non-small cell, while up to 15% are the more aggressive small cell variety targeted by Imdelltra, according to the American Cancer Society. The Amgen drug belongs to a class of treatments called bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body's immune system can kill the cancer. Amgen said 27% of trial patients treated with Imdelltra experienced serious side effects, including low white blood cell counts, compared with 62% of chemotherapy patients. Patients on Imdelltra reported improvements in cough and shortness of breath compared to the chemotherapy group. Cytokine release syndrome, a potentially dangerous condition that occurs when the body's immune system responds over aggressively to infection or immunotherapy drugs, was primarily low-grade and manageable, Amgen said.
